Clinical Trials Browser

Carcinoma, Squamous Cell, Laryngeal Diseases

Carcinoma, Non-Small-Cell Lung

Metastatic Castration-Resistant Prostate Cancer

Stomach Neoplasms

Salivary Gland Neoplasms

Carcinoma, Non-Small-Cell Lung

Triple Negative Breast Neoplasms

Lung Neoplasms

Squamous Cell Carcinoma of Head and Neck, Oropharyngeal Neoplasms

Breast Neoplasms

Stage III Nasal Cavity and Paranasal Sinus Squamous Cell Carcinoma AJCC v6 and v7

Carcinoma, Squamous Cell

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Urinary Bladder Neoplasms

Carcinoma, Non-Small-Cell Lung, Neoplasm, Residual

Carcinoma, Squamous Cell, Head and Neck Neoplasms, Laryngeal Neoplasms, Mouth Neoplasms, Oropharyngeal Neoplasms, Papillomavirus Infections

Metastatic Non-Squamous Non-Small Cell Lung Cancer

Urinary Bladder Neoplasms

Triple Negative Breast Neoplasms

Breast Neoplasms

Advanced Solid Tumour

Esophageal Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Breast Neoplasms

Breast Neoplasms

Stomach Neoplasms

Anatomic Stage I Breast Cancer AJCC v8

Carcinoma, Oropharyngeal Neoplasms

Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

Anatomic Stage I Breast Cancer AJCC v8

Breast Neoplasms, Triple Negative Breast Neoplasms

Carcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Vaccinia

Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

Breast Neoplasms

Adenocarcinoma

HER2-positive Breast Cancer

Breast Neoplasms

Breast Neoplasms

Sinonasal undifferentiated carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Paranasal Sinus Neoplasms

Pathologic Complete Response, Breast Neoplasms

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Small Cell Lung Carcinoma

Urinary Bladder Neoplasms

Breast Neoplasms, Triple Negative Breast Neoplasms

Clinical Trials

Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design

Microwave Ablation Plus Tislelizumab and Docetaxel in Advanced NSCLC After First-Line Immunotherapy Failure

InavoPC

A Phase 2 Study of Neoadjuvant Docetaxel, Oxaliplatin, S-1 in Patients With Unresectable Locally Advanced or Distant Metastasis Limited to Lymph Node Gastric Cancer

Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) or Trastuzumab Deruxtecan for Recurrent, Metastatic, or Unresectable HER2-Expressing Salivary Gland Cancers

IMMUNOLIFE2

Phase II Trial of Ivonescimab in Combination With Carboplatin + Docetaxel in Patients With Early-Stage Triple Negative Breast Cancer

MK-3475-01I

CAMPFIRE

Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) Cancer

ctDNA in HER2+ EBC Neoadjuvant Treatment

Chemotherapy Before Surgery and Radiation Therapy or Surgery and Radiation Therapy Alone in Treating Patients With Nasal and Paranasal Sinus Cancer That Can Be Removed by Surgery

Immunotherapy With Chemotherapy and Chemoradiation for Advanced Squamous Cancer of Nasal Cavity / Paranasal Sinuses (I-NAPA)

VELOCITY-Lung

Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment

EmpowHER 208

Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer

ctDNA-MRD Guided Escalation of Ivonescimab and Docetaxel in Advanced NSCLC With Long-Term Responses to First-line Immunotherapy (CR1STAL-Adaptive)

(NeoScorch HN)

Trial Investigating Visugromab and Nivolumab With or Without Docetaxel in 2L Treatment of Participants With Metastatic NSCLC

Intravesical Gem/Doce in Patients With NMIBC

TARMAC

Assessing the Efficacy and Safety of Anti-HER2 Therapy in Nigerian Women With HER2+ Breast Cancer Before and After Surgery

A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 01(NSCLC)]

A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer

Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer

WAST Cell-Docetaxel Combination Therapy in PD-1 Inhibitor-Resistant Advanced NSCLC

Dalpiciclib Plus AI (Neoadjuvant Endocrine Therapy) Compared With Neoadjuvant Chemotherapy in Early Breast Cancer （EBC）

Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer

De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA

Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial

NeoTRACT

VIRO-25

Safety and Efficacy of Glumetinib Combined With Docetaxel for Injection (Albumin-bound) in Patients With Advanced Gastric Cancer/Gastroesophageal Junction Adenocarcinoma and Other Solid Tumors

ARIADNE

An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction Adenocarcinoma

A Study of BL-M07D1, BL-M07D1+Pertuzumab and BL-M07D1+Pertuzumab+Docetaxel in Patients With Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer

BRE-10

The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer

Toripalimab With Chemotherapy for Sinus Cancer

SHR-A1811 Plus Pertuzumab in the Neoadjuvant Treatment of HER2 Positive BC

Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC

HGNMIBC

PROTECT-1

Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer

GAIN INST

Clinical Study of Camrelizumab Combined With TCb Versus TCb in Neoadjuvant Treatment of Triple-negative Breast Cancer